[Endogenous opiate modulators of insulin secretion in the obese].
The effects of endogenous opiates on insulin response to oral glucose load were studied in obese subjects and in lean healthy volunteers. None of these having a family diabetes. After 3 days on an 1,800 cal./m2, 40% carbohydrate diet all subjects underwent two standard 75 g oral glucose tolerance tests (OGTT), one of which was accompanied by an i. v. administration of 10 mg of, an antagonist of opiates, the naloxone. In one group of obese impaired oral glucose tolerance test occurred. All obese, but not the lean healthy volunteers, showed: 1) increased basal plasma insulin levels, 2) higher insulin response to OGTT, 3) a decrease in insulin response to OGTT after naloxone administration, with significant differences at 60 min (p less than 0.01) and 90 min (p less than 0.025). In none of the subjects significant differences were observed in blood glucose levels after OGTT plus naloxone administration. These data suggest that increased endogenous opiates may affect insulin response to glucose in obese with impaired or normal oral glucose tolerance test. At present there seems to be no satisfactory explanation for unchanged blood glucose levels during OGTT with and without naloxone despite a decrease in insulin secretion in the obese patients.
Satta
M A
MA
Cattedra di Endocrinologia, Università G. D'Annunzio, Chieti, Paris.
Maussier
M L
ML
Scoppola
A
A
Menini
E
E
Liberale
I
I
Lio
S
S
Monaco
F
F
Roche
J
J
D000293:Adolescent; D000328:Adult; D004723:Endorphins / Q000037:antagonists & inhibitors / Q000502:physiology*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009765:Obesity / Q000097:blood*
D004723:Endorphins; D007328:Insulin; D009270:Naloxone
Les opioïdes endogènes modulateurs de la sécrétion d'insuline chez les obèses.